Lexicon Pharmaceuticals (LXRX) Soars on Positive FDA Meeting Outcomes

 Lexicon Pharmaceuticals (LXRX) saw a significant stock increase following favorable news from its meeting with the U.S. FDA about pilavapadin, an experimental treatment for diabetic peripheral neuropathic pain. The FDA did not oppose the company's proposal to move the therapy into Phase 3 trials. These trials will feature two placebo-controlled studies over 12 weeks, focusing on a 10 mg daily dose. Importantly, the FDA has not required additional studies, streamlining the path toward regulatory submission.

https://www.gurufocus.com/news/8540513/lexicon-pharmaceuticals-lxrx-soars-on-positive-fda-meeting-outcomes